ADHD : Summary for Alcobra Ltd. - Ordinary Shares - Yahoo Finance

U.S. Markets close in 3 hrs 44 mins

Alcobra Ltd. (ADHD)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.93-0.97 (-50.98%)
As of 12:16PM EST. Market open.
People also watch
ACRXCNATANTHAFMDAKBA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.90
Open1.06
Bid0.93 x 1300
Ask0.93 x 200
Day's Range0.83 - 1.07
52 Week Range0.83 - 5.75
Volume4,432,645
Avg. Volume391,143
Market Cap25.67M
Beta1.07
PE Ratio (TTM)-1.06
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 24/7 Wall St.1 hour ago

    Tuesday’s Top Biopharma Movers

    A few biotech and pharma companies were on the move Tuesday. A few of the smaller caps made tremendous gains on the day, as the fourth-quarter earnings season is kicking off.

  • MarketWatch4 hours ago

    Alcobra Ltd. stock plummets 43% after failed late-stage trial for its ADHD drug

    Alcobra Ltd. stock plummeted 42.6% in pre-market trade Tuesday after the company said its ADHD drug failed to meet its primary endpoint in a phase 3 trial. The company is "exceedingly disappointed" ...

  • Reuters4 hours ago

    Alcobra's ADHD drug fails late-stage study

    Alcobra Ltd said on Tuesday its experimental attention deficit hyperactivity disorder (ADHD) therapy failed a late-stage study in adult patients and the company's shares plunged about 44 percent in premarket trading. The Israeli drug developer will take a decision on the drug, MDX, after reviewing the full data set, Chief Executive Dr. Yaron Daniely said. MDX did not induce a statistically significant benefit over a placebo in adults with ADHD, a cognitive disorder characterized by poor concentration, hyperactivity and learning difficulties.